MG
Therapeutic Areas
Mosaic ImmunoEngineering Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Acquired Necroptosis Assets (from Oncotelic) | Cancer | Clinical |
Leadership Team at Mosaic ImmunoEngineering
SK
Steven King
President and Chief Executive Officer, Director
PL
Paul Lytle
EVP, Chief Financial Officer, Director
CE
Cyril Empig, Ph.D.
Head of Vaccine Development
SF
Shelley Fussey, Ph.D.
VP, Intellectual Property
RG
Robert Garnick, Ph.D.
Director
RA
Robert A. Baffi, Ph.D.
Director